



PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/777,053
	Filing Date	February 10, 2004
	First Named Inventor	John J. L. Simard
	Art Unit	1644
SHEET 1 OF 1		Examiner Vandervegt, Francois P.
		Attorney Docket No. MANNK.022C1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/PV/	1	WO/03/011331	03-13-2003			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/PV/	2	Schadendorf et al., "Listeria Expression Vector for Immunotherapy, Particularly of Malignant Melanoma, Comprises a DNA Sequence Encoding Tumor-Associate Antigens," XP002401738, Database Geneseq Derwent; July 16, 2001	
/PV/	3	Supplementary European Search Report from European Patent Application No. 02806695.9 dated October 30, 2006	

3158872 sma112906

Examiner Signature /F. Pierre VanderVegt/	Date Considered 03/19/2007
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/777053
	Filing Date	February 10, 2004
	First Named Inventor	Simard, John J.L.
	Art Unit	1644
	Examiner	Francois P. Vandervegt
SHEET 1 OF 1	Attorney Docket No.	MANNK.022C1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/PVI/	1	10/837,217	04-30-2004	Simard et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/PVI/	2	WO 2004/018666 A1	03-04-2004	Simard et al.		
/PVI/	3	WO 2004/022709 A2	03-18-2004	Simard et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/PVI/	4	BORBULEVYCH et al., "Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: Implications for vaccine design," <u>The Journal of Immunology</u> , 2005, pp. 4812-4820, The American Association of Immunologists, Inc.	

3311223
011607

Examiner Signature /F. Pierre VanderVegt/	Date Considered 03/19/2007
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.